Partnering With CSL
Why Partner with CSL?
Innovation has been in our DNA for more than a century. We have the full spectrum of strengths from research and clinical development to manufacturing and commercialization across six therapeutic areas of expertise. We know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and we work closely with organizations outside our walls that have unique technologies, assets and equipment to address our patients’ unmet needs around the globe.
Our approach is to collaborate with industry, academia or other groups developing great products and technologies that have the capacity to address unmet public health need. We will work to find mutually beneficial arrangements that include traditional licensing, joint ventures, strategic investments or other suitable structures that most effectively leverage our combined capabilities.
CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Today, CSL – including our four businesses: CSL Behring, CSL Seqirus, CSL Vifor and CSL Plasma – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.
Focused on serving patients’ needs by using the latest technologies, CSL Behring discovers, develops and delivers innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs. CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma.
At CSL Behring, we are interested in products and technologies that can have an immediate impact as well as clinical, or pre-clinical, products and technologies that can address significant unmet medical need in our areas of interest.
As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. With state-of-the-art production facilities in the U.S., the U.K. and Australia, and leading R&D capabilities, CSL Seqirus utilizes egg, cell and adjuvant technologies to offer a broad portfolio of differentiated influenza vaccines in more than 20 countries around the world.
CSL Seqirus also in-licenses a wide range of pharmaceutical and vaccine products from international partners for distribution in Australia and New Zealand and has a dedicated professional team who can offer flexible partnering solutions from regulatory to commercialisation.
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives.
CSL Plasma operates one of the world’s largest and most sophisticated plasma collection networks, with nearly 350 plasma collection centers in the U.S., Europe and China. Headquartered in Boca Raton, Florida, CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics business and a member of CSL. Plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries.